FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Results of Operations and Financial Condition

On August 7, 2017, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended June 30, 2017.A copy of such press release is furnished as Exhibit99.1 to this report and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Sectionor Sections11 and 12(a)(2)of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in Exhibit99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by FibroGen, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

FIBROGEN INC ExhibitEX-99.1 2 fgen-ex991_6.htm EX-99.1 fgen-ex991_6.htm Exhibit 99.1 FIBROGEN REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Company Announces Positive Topline Results from Phase 2 Study in IPF Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO,…To view the full exhibit click here
About FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.